

REMARKS

The corrections and additions to the specification requested herein are corrections needed to conform the specification to the Sequence Listing. If not otherwise detailed below, insertion of sequence identifiers was made to clarify the relationship between certain cited or referenced sequences and the Sequence Listing.

The amendments to page 7, lines 18-19 and 22 were made better distinguish the APP fragments described and shown in the figures.

The amendment at page 7, line 23 was made to correct the position of the recited sequence within the peptide fragment. The error is obvious when the amino acids shown are counted, with reference, for example, to FIG. 5.

The descriptors of SEQ ID NOS: 76-102 were added at page 8, in view of their addition to the sequence listing, as described with reference to Table 3, below.

Correction of the sequence recited at page 24, line 18 (SEQ ID NO: 56) was made to correct an obvious error. The internal peptide is correctly shown in FIG. 5 (block described as "internal peptide sequence") with a "G" (glycine) in position 2 thereof. The transcription error was inadvertent and without deceptive intent.

The Sequence identifiers SEQ ID NOS. 99-102 were added to Table 3, page 25, in order to describe these sequences in the Sequence Listing.

The sequence recited at pages 32-33 was replaced with the identifier, SEQ ID NO: 80.


The primer sequences at page 56 were placed in tabular form by inserting the heading "Table 6A" and their identifiers were added.

The insertion of sequence identifiers at lines 22 and 23 of page 68, as well as at line 30 of page 70, were necessary to comply with the requirements 37 C.F.R. §1.821.

Claims 40, 69, 79 and 94 have been amended to insert sequence identifiers in the place of the recited peptide fragment sequences.

Applicants submit that no new matter is added by the foregoing amendments to the specification. Accordingly, entry of this amendment is respectfully requested.

Respectfully submitted,



Carol A. Stratford
Registration No. 34,444

CUSTOMER NUMBER: **21835**
ELAN PHARMACEUTICALS, INC.
800 Gateway Blvd
South San Francisco, California 94080
Telephone: **(650) 877-7432**
Telefax: (650) 553-7165